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Background
Pretreatment assessment of cervical lymph node metastasis is important for therapeu-
tic planning and prognostication in patients with oral squamous cell carcinoma (OSCC) 
(Snow et  al. 1992). Preoperative nodal status is usually evaluated by means of clinical 
examinations such as palpation, computed tomography (CT), ultrasonography (US), and 
magnetic resonance imaging (MRI). Unfortunately, CT and MRI, which evaluate mor-
phologic parameters such as nodal size, internal architecture and contrast enhancement 
pattern, have been shown to have only limited value for this purpose (Castelijins and 
van den Brekel 2002). At present, neck dissection with histologic examination of lymph 
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nodes is still the most reliable staging procedure. However, it is unavoidably invasive, 
and therefore a noninvasive procedure capable of providing high-quality prognostic data 
approaching this gold standard would be of immense value.
Positron emission tomography (PET) using the glucose analog, fluorine-18-labeled 
fluorodeoxyglucose (FDG), is a functional imaging modality that provides informa-
tion about tissue glucose metabolism. Integrated PET/CT has been applied success-
fully for evaluation of squamous cell carcinoma of the head and neck (HNSCC), and 
recent reports have suggested that it is also useful for evaluation of nodal involvement 
in OSCC. There is growing evidence that FDG-PET or PET/CT is a more reliable and 
accurate imaging tool than CT for evaluation of cervical neck lymph node metastasis in 
OSCC (Matsubara et al. 2012; Ng et al. 2005; Yamazaki et al. 2008). On the other hand, 
several reports have indicated that FDG-PET or PET/CT offers no advantage, especially 
for evaluation of the N0 neck in early OSCC (Krabbe et al. 2008; Nahmias et al. 2007; 
Schöder et al. 2006), and therefore its diagnostic value remains controversial.
The maximum standardized uptake value (SUVmax) is widely used for measuring the 
uptake of FDG by malignant tissue (Gambhir 2002). Increased FDG uptake values reflect 
the viability of cancer cells, and can be imaged and quantified using PET. Recent studies 
of OSCC have demonstrated that the SUVmax of the primary tumor is related to pro-
liferative cell activity and cellularity, and also to the prognosis of patients (Suzuki et al. 
2009). However, few studies have reported the clinical significance of SUVmax for diag-
nosis of cervical lymph node metastasis in OSCC (Matsubara et al. 2012), and thus the 
true usefulness of SUVmax in this context remains unclear.
Clinically, it is recognized that level IIa nodes located around the internal vein and 
anterior spinal accessory nerve at levels between the skull base and the hyoid bone often 
show relatively higher nonspecific FDG uptake due to reactive hyperplasia in compari-
son with nodes at other levels. Therefore, as reported previously by Jeong et al. in a study 
of patients with HNSCC, it may be better to use a SUV cut-off that differs according 
to the node level, for differentiating malignant from benign lymph nodes (Jeong et al. 
2007).
The aim of the present study was to investigate the diagnostic accuracy of cervical 
node evaluation by FDG-PET/CT using SUVmax in patients with OSCC in compari-




This retrospective study approved by our institutional review board involved 36 patients 
(23 males, 13 females; average age at diagnosis 67.3  years, range 37–88  years), from 
whom informed consent was waived. All of the study subjects with biopsy-proven OSCC 
underwent resection of the primary tumor and cervical node dissection within 4 weeks 
after undergoing FDG-PET/CT examinations at our institution between November 
2011 and July 2014. The primary tumor was located in the oral tongue in 16 patients, the 
gingiva in 12, and the floor of mouth in 8. Patient demographics and clinicopathologic 
variables are shown in Table 1.
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The studied patients underwent unilateral (n = 32) or bilateral (n = 4) neck dissection. 
A total of 40 sites in the neck lymph node basin were subjected to type III modified radi-
cal dissection (n = 19), supraomohyoid neck dissection (n = 15), extended supraomohy-
oid neck dissection (n = 5), or lateral neck dissection (n = 1). Pathologically, 3 patient 
had T1, 9 had T2, 13 had T3, and 11 had T4 tumors; nodal involvement was N0 in 12 
patients, N1 in 12, N2b in 9, and N2c in 3.
FDG‑PET/CT
Whole-body imaging was performed using a combined PET/CT scanner (Discovery 
PET/CT 690, GE Healthcare, Waukesha, WI, USA). CT covered a region ranging from 
the meatus of the ear to the midthigh. The technical parameters of the 16-detector-row 
helical CT scanner were a helical pitch of 28 or a beam pitch of 1.75, a gantry rotation 
speed of 0.6 s, and a slice thickness of 3.27 mm. The PET component of the combined 
imaging system allowed simultaneous acquisition of 47 transaxial PET images with 
an interslice spacing of 3.27 mm in one bed position, and provided an image from the 
Table 1 Patient characteristics
SOHND supramohyoid neck dissection, MRND modified radical neck dissection with preservation of sternocleidomastoid 






 Mean 67.3 ± 10.0
 Range 37–88
Primary tumor sites
 Oral tongue 16
 Gum 12















Type of neck dissection
 SOHND (levels I–III) 15
 Extended SOHND (levels I–IV) 5
 MRND, typeIII(levels I–V) 19
 LND (levels II–IV) 1
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meatus of the ear to the midthigh with 7–8 bed positions. The transaxial field of view 
and axial field of view of the PET images reconstructed for fusion were 60 and 15.0 cm, 
respectively, with a matrix size of 192 × 192. To avoid artifacts caused by the urinary 
tract, patients were asked to drink 500 ml of water 1–2 h prior to image acquisition, and 
to void just before the start of acquisition. After at least 4 h of fasting, patients received 
an intravenous injection of 222–333 MBq (6–9 mCi) of 18F-FDG. The blood glucose lev-
els were checked in all patients before FDG injection, and no patients showed a blood 
glucose level of more than 200 mg/dL.
About 50 min later, initial low-dose non-enhanced CT was performed at 120 kV and 
Smart mA (20–120 mA, Noise Index 30) using the normal expiration position for atten-
uation correction of the PET image. A whole-body emission PET scan was performed 
immediately after the low-dose non-enhanced CT scan, with a 2-min acquisition per 
bed position using the three-dimensional acquisition mode. Attenuation-corrected PET 
images were reconstructed with an ordered-subset expectation maximization itera-
tive reconstruction algorithm, VUE Point FX-S, with TOF and sharp IR (18 subsets, 2 
iterations).
For image fusion, a 3.27-mm slice was reconstructed. The CT and PET images were 
transferred to a commercially available workstation (Advantage Windows Workstation, 
version 4.5, GE Healthcare Technology) in order to access all of the data.
Image analysis
PET images were interpreted retrospectively by two experienced nuclear medicine phy-
sicians. For semiquantitative analysis of FDG uptake, regions of interest (ROIs) were 
defined on the target lesions (primary lesion and neck lymph node) in the transaxial PET 
images. The maximum standardized uptake value (SUV) was calculated for quantitative 
analysis of tumor FDG uptake, as follows:
where C is the tissue activity concentration measured by PET, and ID is the injected 
dose.
For nodal disease, the highest SUVmax was used for quantitative evaluation.
Nodes were considered to harbor metastasis if their longest axial diameter was 
>15 mm for levels I and II or >10 mm for levels III-V, if they appeared spherical (rather 
than flat or bean-like) in shape, or showed rim enhancement with central necrosis or 
cystic degeneration, and if they were abnormally grouped (Sakai et al. 2000; Som et al. 
2000).
If there were multiple lymph nodes at a specific level, the node suspected to have the 
highest malignant potential on CT or showing the highest SUVmax on PET/CT was 
assessed.
Surgical procedure and histology
Neck dissection was planned by our head and neck surgical team based on the clini-
cal and imaging findings (Ferlito et al. 2006). Supraomohyoid neck dissection (SOHND, 
levels I–III) was performed for patients who were node-negative in the neck, or who 
had a single positive node in the upper neck. Extended supraomohyoid neck dissection 
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(extended SOHND, levels I–IV) or modified radical neck dissection (MRND, levels 
I–V) was performed for patients with >1 involved node or extracapsular nodal spread, 
depending on the extent of the cervical adenopathy. Bilateral neck dissection was per-
formed for patients in whom the primary tumor crossed the midline, or those consid-
ered likely to have node metastases in the contralateral neck. The operative surgeon 
labeled the primary tumor and neck dissection specimens so as to allow reference to the 
schema used for interpretation of the FDG-PET/CT studies. Lymph nodes and tumors 
were dissected from the specimens and stained with hematoxylin and eosin for histo-
logic analysis. Serial histologic sections were used. An experienced pathologist exam-
ined the specimens and recorded the number, size, and capsular penetration of the 
affected nodes.
Statistical analysis
On the basis of the neck level system (Sakai et  al. 2000), we compared the results of 
preoperative FDG-PET/CT and CT examinations with those of the corresponding his-
topathologic examinations. Because precise spatial correlation between PET/CT and 
histopathology is impossible, analysis was restricted to nodal levels and neck sides. If the 
findings of PET were suggestive of metastasis, and if histopathology showed at least one 
lymph node with metastasis at a given nodal level in the neck, a true positive finding was 
recorded, regardless of the number of metastatic foci at that level.
Receiver operating characteristic (ROC) curve analysis was performed to evaluate 
whether SUVmax was able to allow diagnosis of nodal metastasis and to identify the best 
cutoff value.
Analysis was performed on a patient, neck side, and lymph node level basis. Sensi-
tivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and 
accuracy were calculated using standard statistical formulae, and the 95  % confidence 
interval (CI) was determined for each parameter. Differences at p < 0.05 were considered 
statistically significant. All analyses were performed using the SAS software package ver-
sion 9.2 (SAS Institute, Cary, NC, USA).
Results
Overall, 40 neck sides were dissected (32 unilateral, 4 bilateral), involving 250 nodal lev-
els and a total of 1257 lymph nodes (mean, 31.3 lymph nodes per neck side). Histopatho-
logic analysis revealed lymph node metastases in 13 of the 36 patients (36.1 %), 15 of the 
40 neck sides (37.5 %), and 28 of the 250 nodal levels (11.2 %). Overall, metastases were 
found in 35 of the 1257 dissected lymph nodes (2.8 %).
Cervical lymph nodes were dissected at 250 neck levels (Ia:Ib:IIa:IIb:III:IV:V = 37:42: 
40:39:40:27:25), and malignant cells were found at 28 neck levels (Ia:Ib:IIa:IIb:III:IV:V = 
2:9:11:1:5:0:0).
Primary tumors
All 36 primary tumors were clearly identified by FDG-PET; the intensity of FDG uptake 
in these lesions ranged from moderate to very intense, with an SUVmax range of 6.41–
28.73 (mean, 15.5 ± 6.6).
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Metastatic neck disease
Level‑by‑level analysis
The SUVmax of malignant lymph nodes showing significant FDG uptake (mean SUV-
max, 6.03 ± 4.22; range 1.13–17.02) was significantly higher than that of benign lymph 
nodes (mean SUVmax, 1.98 ±  0.84: range 0.79–5.24; p < 0.0001). Nodes with a SUV-
max of >5.25 were all confirmed pathologically to harbor metastases. The SUVmax of 
metastatic lymph nodes with and without extracapsular spread were 11.41 ± 3.93 (8.09–
17.02) and 5.13 ± 3.60 (1.13–12.17), respectively (p = 0.040).
Using a best discriminative SUVmax cut-off of 3.5 for discriminating metastatic from 
benign cervical nodes based on ROC curve analysis with an area under ROC curve 
(AUC) of 0.874, the sensitivity, specificity and accuracy of FDG-PET/CT for identifica-
tion of nodal metastases on a level-by-level basis were 67.9 % (19/28), 94.6 % (210/222), 
and 91.6  % (229/250), respectively. The corresponding figures for CT were 42.9  % 
(12/28), 96.8  % (215/222), and 90.8  % (227/250), respectively. The sensitivity of FDG-
PET/CT was significantly better than that of CT (p = 0.023), but the differences in spec-
ificity and accuracy were not statistically significant (Table 2). Three representative cases 
are shown in Figs. 1, 2 and 3: Fig. 1 shows that both CT and FDG-PET gave true-positive 
results, whereas Fig. 2 shows that CT gave a false-negative result and FDG-PET a true-
positive result.
Level‑based analysis
Table  3 shows the level-based SUVmax for metastatic and benign lymph nodes, and 
the level-based best SUVmax cut-off for discriminating metastatic from benign nodes. 
Because the SUVmax for benign nodes at level IIa was slightly high (mean: 2.85, range 
0.95–5.24), the optimum SUVmax cut-off was slightly high (4.0). Because the SUVmax 
for metastatic nodes at level IIb was relatively low (2.84), the optimum SUVmax cut-off 
was slightly low (2.8). Table 3 also shows the diagnostic performance of FDG-PET/CT 
using the level-based modified SUVmax cut-off for identification of nodal metastases in 
comparison with the figures for CT. Using the level-based modified SUVmax cut-off (3.5 
Table 2 Level-by-level diagnostic performance of  three methods (CT, PET/CT with  best 
SUVmax cut-off, and PET/CT with level-based modified SUVmax cut-off)
TP true positive, FN false negative, TN true negative, FP false positive, PPV positive predictive value, NPV negative predictive 
value, CI confidence interval
a The sensitivity of FDG‑PET/CT with best SUVmax cut‑off (3.5) was significantly higher than that of CT (p = 0.023)
b The sensitivity of FDG‑PET/CT with level‑based modified SUVmax cut‑off was significantly higher than that of CT 
(p = 0.013)
c The accuracy of FDG‑PET/CT with level‑based modified SUVmax cut‑off was significantly higher than that of CT (p = 0.041)
TP FN TN FP Sensitivity Specificity PPV NPV Accuracy
95 % CI 95 % CI 95 % CI 95 % CI 95 % CI
CT 12 16 215 7 42.9a,b 96.8 63.2 93.1 90.8c
24.6–61.2 94.5–99.1 41.5–84.9 89.8–96.4 87.2–94.4
FDG‑PET/CT using best  
SUVmax cut‑off (3.5)
19 9 210 12 67.9a 94.6 61.3 95.9 91.6
50.6–85.2 91.6–97.6 59.8–62.8 93.3–98.5 88.2–95.0
FDG‑PET/CT usinglevel‑ 
based modified  
SUVmax cut‑off
20 8 213 9 71.4b 95.9 69 96.4 93.2c
54.7–88.1 93.3–98.5 67.6–70.5 93.9–98.9 90.1–96.3
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for levels Ia, Ib, III, IV, and V, 4.0 for level IIa, and 2.8 for level IIb), the sensitivity, speci-
ficity, and accuracy of FDG-PET/CT were 71.4 % (20/28), 95.9 % (213/222), and 93.2 % 
(233/250), respectively, the sensitivity (p = 0.013) and accuracy (p = 0.041) being signifi-
cantly higher than those for CT (Table 2). Figure 3 shows that FDG-PET using SUVmax 
cut-off (3.5) gave a false-positive result and only both CT and FDG-PET using modified 
SUVmax cut-off (4.0) gave a true-negative result.
Patient‑based analysis
The sensitivity, specificity and accuracy of FDG-PET/CT for identification of nodal 
metastases on a patient-by-patient basis were 84.6 % (11/13), 87.0 % (20/23), and 86.1 % 
(31/36), respectively, and the corresponding figures for CT were 76.9 % (10/13), 91.3 % 
Fig. 1 A 77‑year‑old man with level IIa node metastasis arising from cancer of the tongue (pT4N2b). a CT of 
PET/CT shows one swollen lymph node 20 mm in longest diameter at right level IIa (arrow), suggesting the 
presence of nodal cancer spread. b FDG‑PET/CT shows intense FDG uptake (SUVmax:11.91) corresponding to 
the right level IIa node seen in a (arrow), suggesting the presence of nodal cancer spread. Examination of the 
histopathological specimen confirmed extensive lymph node involvement by cancer in this node. Both CT 
and FDG‑PET/CT were true‑positive
Fig. 2 A 63‑year‑old man with right level IIa node metastasis arising from cancer of the gum (pT3N2c). a CT 
of PET/CT shows one swollen lymph node 10 mm in longest diameter at right level IIa (short arrow) and one 
swollen lymph node 11 mm in longest diameter at left level IIa (long arrow), suggesting absence of nodal 
cancer spread. b FDG‑PET/CT shows moderate FDG uptake (SUVmax:5.34) corresponding to the right level 
IIa node seen in a (short arrow), suggesting the presence of nodal cancer spread. And mild FDG uptake (SUV‑
max:2.31) corresponding to the left level IIa node seen in b (long arrow), suggesting absence of nodal cancer 
spread. Histopathological examination of the specimen confirmed extensive lymph node involvement by 
cancer in only the right node. CT gave a false‑negative result for the right node, whereas FDG‑PET/CT gave a 
true‑positive result. Both CT and FDG‑PET/CT gave true‑negative results for the left node
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(21/23), and 86.1 % (31/36), respectively. Sensitivity and specificity for the two methods 
were almost the same and accuracy was exactly the same.
Discussion
In the present study, we compared the diagnostic performance of SUVmax between 
FDG-PET and CT for evaluation of cervical lymph node metastases in OSCC using his-
topathology as the gold standard. Although the specificity of FDG-PET on level-by-level 
basis was slightly inferior to that of CT (94.6 vs. 96.8 %), the sensitivity of SUVmax was 
significantly higher than that of CT (67.9 vs. 42.9 %, p = 0.023). Moreover, FDG-PET/
CT with level-based modified SUVmax cut-off values had significantly higher sensitivity 
(71.4 vs. 42.9 %, p = 0.013) and accuracy (93.2 vs. 90.8 %, p = 0.041) than CT. Whereas, 
there was no difference in accuracy on patient-based analysis.
Currently, CT and MRI are commonly used for evaluation of the primary tumor and 
cervical node status. These modalities characterize the cervical lymph nodes on the basis 
of morphological criteria such as node size, the presence of central necrosis, and the 
presence of indistinct nodal margins. The reported sensitivity and specificity of CT and 
MRI for detection of cervical lymph node metastases in OSCC are 36–78 and 47–99 %, 
respectively (Castelijins and van den Brekel 2002; Conti et al. 1996; Hannah et al. 2002; 
Krabbe et al. 2008; Matsubara et al. 2012; Ng et al. 2005; Yamazaki et al. 2008). Doppler 
US with fine-needle aspiration can overcome some of these limitations, but the results 
are dependent on the skill level of the sonographer, and this may be impractical in some 
cases because the number of questionable nodes may be high.
Several studies have evaluated the diagnostic performance of FDG-PET for detect-
ing cervical lymph node metastases of OSCC (Krabbe et al. 2008; Matsubara et al. 2012; 
Nabmias et al. 2007; Ng et al. 2005; Yamazaki et al. 2008; Schöder et al. 2006). Data from 
those studies demonstrated large variations in sensitivity and specificity, being 50–95 % 
and 82–99  %, respectively. Sun et  al. (Sun et  al. 2015) reviewed 24 studies of 1270 
patients with HNSCC to assess nodal metastasis and reported that the mean (95 % CI) 
Fig. 3 A 66‑year‑old man without neck node metastasis arising from the tongue (pT2N0). a CT of PET/CT 
shows two swollen lymph nodes 10 and 9 mm in longest diameter at left level IIa (arrows), suggesting the 
absence of nodal cancer spread. b FDG‑PET/CT shows moderate FDG uptake (SUVmax:3.71 and 3.56) cor‑
responding to the two left level IIa nodes seen in a (arrows). Examination of the histopathological specimen 
confirmed no lymph node metastasis. CT gave true‑negative result. FDG‑PET/CT using SUVmax cut‑off (3.5) 
gave false‑positive result, whereas FDG‑PET/CT using modified SUVmax cut‑off (4.0) gave true‑negative result
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pooled per-patient, per-neck-side, and per-neck-level sensitivities/specificities of FDG-
PET/CT were 91  % (82–95  %)/87  % (80–92  %), 84  % (75–90  %)/83  % (77–88  %), and 
80 % (71–87 %)/96 % (94–97 %), respectively. Across 13 studies (3,460 neck levels) with 
per-neck-level data, the sensitivity and specificity of FDG-PET/CT were 84 % (72–91 %) 
and 96 % (95–97 %), and of conventional imaging (CT, MRI, and CT/MRI) were 63 % 
(53–72 %) and 96 % (95–97 %), respectively.
Only one study by Matsubara et al. (2012) has used SUVmax for evaluation of cervical 
lymph nodes of OSCC, and the authors proposed the new assessment method combin-
ing SUV and nodal size. Jeong et  al. (2007) have used level-based SUV for evaluation 
of cervical lymph nodes in patients with HNSCC, including cancers of the oral cavity, 
larynx, oropharynx, hypopharynx, and unknown primary sites. Although in our present 
series we identified an optimum SUVmax cut-off value of 3.5 by ROC curve analysis, 
this figure was coincidentally the same as that reported by Jeong et al. (2007). Similarly 
to our study, they adopted 4.0 as the threshold SUV for jugulodigastric nodes, which 
is where reactive hyperplasia frequently occurs, as was seen in our series. Because the 
SUVmax of benign nodes at level IIa tends to be slightly high, it is better to establish a 
slightly higher SUVmax cut-off for this level.
Although FDG-PET is more useful than CT for diagnosis of cervical lymph node 
metastasis, the diagnostic capability of FDG-PET is limited not only by cellular activity 
but also by tumor volume. FDG uptake by small deposits of tumor cells is often poorly 
depicted owing to partial volume effects (Takamochi et al. 2005). Moreover, its registra-
tion is limited to a certain lymph node size, because the spatial resolution of recent PET 
scanners is technical limited to 4–5 mm (Yamazaki et  al. 2008). A previous study has 
suggested that occult metastases have tumor involvement extending over only 1–2 mm 
(Stoeckli et  al. 2002). Therefore, FDG-PET scanning may be unable to detect occult 
nodal metastases. In the future, the development of dual time point PET, new tumor-
specific tracers and PET scanners with a higher resolution may increase the potential to 
detect occult lymph node metastases.
In the present series, false-positive findings were encountered in several cases. The 
intensity of tracer uptake by inflammatory lymph nodes is virtually the same as that in 
metastatic lesions. Common exposure to carcinogens in tobacco smoke and alcohol may 
be responsible for chronic, low-level lymphadenitis in patients with head and neck can-
cer. Accordingly, histologic analysis of false-positive nodes showed follicular and para-
follicular hyperplasia of lymphoid tissue in all false-positive cases. Similar histologic 
changes in false PET-positive nodes have been reported in lung cancer staging studies 
(Gonzalez-Stawinski et al. 2003).
There were several limitations to the present study. First, it had a retrospective design 
and involved a relatively small number of patients at a single institution. Second, as every 
patient was a candidate for surgery including neck dissection, a patient selection bias 
was unavoidable. Third, full-dose contrast-enhanced CT was performed for 18 patients 
(50 %) at the time of FDG-PET/CT and was not used in our analysis. Given the low-dose 
non-enhanced CT used, visualization of nodes on CT may have been reduced compared 
with visualization of nodes on full-dose contrast-enhanced CT. Fourth, although node-
based analysis is an ideal approach, it was very difficult to correlate any given lymph 
node depicted in an imaging study with the same node in a neck dissection specimen. 
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Therefore, correlation of imaging results with pathological findings based on cervical 
level may be more reasonable if it is done in terms of sensitivity and specificity. Fifth, the 
appropriate cutoff values in any study must be determined for each individual PET scan-
ner at each institution.
Conclusion
FDG PET/CT with SUVmax, especially the modified SUVmax cut-off optimal for each 
cervical level, is a very useful tool for preoperative evaluation of cervical lymph node 
metastasis in patients with OSCC. However, its sensitivity was still not high enough to 
replace pathologic lymph node staging based on neck dissection.
This study was approved by the appropriate Ethics Committee (Ethics Committee of 
the Kobe University Graduate School of Medicine) and thus performed in accordance 
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments.
All persons gave their informed consent prior to inclusion in the study. Details that 
might disclose the identity of the subjects under study have been omitted.
Current study has been performed in accordance with the ethical standards.
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